In this webinar you’ll learn:
- What are your top 3 pieces of advicefor accessing capital as a MedTech company?
- How can companies most effectivelyevidence the value of their products?
- What role should early investment partners be playing in this process?
- Is a focus on R&D investment to drive product innovation enough to secure finance, survive and grow as a MedTech?
- Are there alternative route to capital(e.g. Family Offices, HNWs) that MedTech companies looking for funding should be exploring?
What strategies should companies be considering to better protect themselves and become more investable propositions?
Where is the majority of theinvestment in the sector currently coming from?
Is it simply a different group and type of investor that should be targeted?
When should larger MedTechs be looking at acquisitions for growth and when should smaller companies belooking at a corporate sale as an exit?
How important are, and will in future,accelerator and incubator programsfor the next generation of MedTech innovation?
How do devices, diagnostics, data and platform tech companies fundamentally differ and what are the specific challenges to each in terms of securing investment?
Introducing confirmed speakers for the webinar:
Martin Frost, CEO, Cambridge Medical Robotics
Martin Frost has been involved in founding, financing and leading a wide range of technology companies in Cambridge for over 15 years, including Absolute Sensors (sold to Synaptics Inc.), Sensopad (sold to TT Electronics), Sphere Medical (now listed on the AIM market), and RedCloud Technology. Martin is a Director of Easdale Ventures and Omnisense, both of which he co-founded.
Peter Dines, Investment Director, Head of Life Sciences, Mercia
As a highly successful entrepreneur and investor, Peter brings 20 years’ experience in the healthcare sector, holding numerous directorships across a wide range of life sciences businesses. Over this period, Peter has been involved with a number of high profile turnarounds and exits within the sector, including the acquisition of Surgicraft’s loss making business where, as Managing Director, sales quadrupled within three years and the business was subsequently sold to ISIS Equity Partners.
Wolfgang Rencken, CEO, Sphere Medical
Dr Wolfgang Rencken is CEO of Sphere Medical having joined the Board in February 2014. He has extensive experience in the healthcare and medical diagnostic equipment industries. He has been responsible for the development and launch of many innovative medical devices and has a proven record of revenue and profit growth.
Christoph Ruedig, Partner, Albion Ventures
Christoph joined Albion Ventures as an Investment Manager in October 2011 and now, as Partner, focuses on investments in healthcare and renewables. He initially practised as a radiologist, before spending 3 years at Bain & Company. Most recently he has worked for General Electric’s healthcare division, where he was responsible for mergers and acquisitions in the medical technology and healthcare IT sectors.